• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Gastroenterological Surgery >Prognostic impact of p53 and/or NY‐ESO‐1 autoantibody induction in patients with gastroenterological cancers
【24h】

Prognostic impact of p53 and/or NY‐ESO‐1 autoantibody induction in patients with gastroenterological cancers

机译：P53和/或NY-ESO-1自身抗体诱导胃肠病学癌症患者的预后影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Aim We evaluated the clinicopathological and prognostic significance of serum p53 (s‐p53‐Abs) and serum NY‐ESO‐1 autoantibodies (s‐NY‐ESO‐1‐Abs) in esophageal squamous cell carcinoma (ESCC), gastric cancer and hepatocellular carcinoma (HCC). Patients and Methods A total of 377 patients, 85 patients with ESCC, 248 patients with gastric cancer, and 44 patients with HCC were enrolled to measure s‐p53‐Abs and s‐NY‐ESO‐1‐Abs titers by the enzyme‐linked immunosorbent assay before treatment. The clinicopathological significance and prognostic impact of the presence of autoantibodies were evaluated. Expression data based on the Cancer Genome Atlas and the prognostic impact of gene expression was also examined for discussion. Results The positive rates of s‐p53‐Abs were 32.9% in ESCC, 15% in gastric cancer, and 4.5% in HCC. The positive rates of s‐NY‐ESO‐1‐Abs were 29.4% in ESCC, 9.7% in gastric cancer, and 13.6% in HCC. The presence of s‐p53‐Abs was not associated with tumor progression in these three cancer types. On the other hand, the presence of s‐NY‐ESO‐1‐Abs was significantly associated with tumor progression in ESCC and gastric cancer. The presence of s‐p53‐Abs and/or s‐NY‐ESO‐1‐Abs was significantly associated with poor prognosis in gastric cancer but not in ESCC nor HCC. Conclusions The presence of s‐p53‐Abs and/or s‐NY‐ESO‐1‐Abs was associated with tumor progression in ESCC and gastric cancer. These autoantibodies might have poor prognostic impacts on gastric cancer (UMIN000014530).
机译：背景和目的我们在食管鳞状细胞癌（ESCC），胃癌中，评估了血清P53（S-P53-ABS）和血清NY-ESO-1 Auto artibodies（S-NY-ESO-1-ABS）的临床病理和预后意义和肝细胞癌（HCC）。患者和方法共有377名患者，85例ESCC患者，248例胃癌患者，44例HCC患者通过酶联测量S-P53-ABS和S-NY-ESO-1-ABS滴度治疗前免疫检测。评估了自身抗体存在的临床病理学意义和预后影响。还研究了基于癌症基因组地图集的表达数据和基因表达的预后影响进行讨论。结果S-P53-ABS的阳性率在ESCC中为32.9％，胃癌15％，HCC为4.5％。 S-NY-ESO-1-ABS的阳性率在ESCC中为29.4％，胃癌中9.7％，HCC中的13.6％。 S-P53-ABS的存在与这三种癌症类型中的肿瘤进展无关。另一方面，S-NY-ESO-1-ABS的存在与ESCC和胃癌中的肿瘤进展显着相关。 S-P53-ABS和/或S-NY-ESO-1-ABS的存在与胃癌的预后差异显着相关，但不在ESCC或HCC中。结论S-P53-ABS和/或S-NY-ESO-1BS的存在与ESCC和胃癌中的肿瘤进展相关。这些自身抗体可能对胃癌的预后影响差（UMIN0014530）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号